


In the Claims

Applicant has submitted a new complete claim set indicating marked up claims with insertions and deletions indicated by underlining and strikeouts, respectively.

1.-12. (Cancelled)

13. (Currently Amended) A method for treating an infectious disease comprising administering to a subject in need thereof and who is HIV-negative a composition comprising an agent of Formula I in an effective amount to inhibit progression of the infectious disease, and a pharmaceutically acceptable carrier,

wherein the agent of Formula I is administered by injection or in an enterically coated form, and wherein the agent of Formula I is:



wherein Am and A₁ are L- or D- amino ~~acids~~ acid residues, m is an integer between 0 and 10, inclusive; A ~~is may be~~ an L- or D-amino acid residue such that each A in Am ~~A_m~~ may be an amino acid residue different from another or all other A in Am ~~A_m~~; A₁ is bonded to the R with a C bond that is in the L-configuration; and R ~~is an can be~~ is organo boronate[[s]], organo phosphonate[[s]], fluoroalkylketone[[s]], aliphaketo[[s]] moiety, N-peptidyl-O- (acylhydroxylamine) N-peptidyl-O- (acylhydroxylamines), azapeptide[[s]], azetidine[[s]], fluoroolefin[[s]], dipeptide isoester[[s]], peptidyl (alpha-aminoalkyl) phosphonate ester[[s]], aminoacyl pyrrolidine-2-nitrile[[s]] or ~~and~~ 4-cyanothiazolidide[[s]], provided that R reacts ~~it is capable of reacting~~ with a functional group in the reactive site of FAP-α or other post proline-cleaving enzyme, and

wherein after administration the agent is present in the subject at a concentration above 10^{-8} M.


14-163. (Cancelled)

164. (Currently Amended) A method of preventing an infectious disease in a subject at risk of developing an infectious disease comprising

identifying a subject at risk of developing an infectious disease and who is HIV negative,
and

administering a composition comprising an agent of Formula I to the subject in an amount effective to induce IL-1, and a pharmaceutically acceptable carrier,

wherein the agent of Formula I is administered by injection or in an enterically coated form, and wherein the agent of Formula I is:



wherein Am and A₁ are L- or D- amino acid residues ~~acids~~, m is an integer between 0 and 10, inclusive; A ~~is may be~~ an L- or D-amino acid residue such that each A in Am A_m may be an amino acid residue different from another or all other A in Am A_m; A₁ is bonded to the R with a C bond that is in the L-configuration; and R is an ~~can be~~ organo boronate[[s]], organo phosphonate[[s]], fluoroalkylketone[[s]], aliphaketo[[s]] moiety, N-peptidyl-O- (acylhydroxylamine) N-peptidyl-O- (acylhydroxylamines), azapeptide[[s]], azetidine[[s]], fluoroolefin[[s]], dipeptide isoestere[[s]], peptidyl (alpha-aminoalkyl) phosphonate ester[[s]], aminoacyl pyrrolidine-2-nitrile[[s]] or ~~and~~ 4-cyanothiazolidide[[s]], provided that R reacts ~~it is~~ capable of reacting with a functional group in the reactive site of FAP-α or other post proline-cleaving enzyme, and

wherein after administration the agent is present in the subject at a concentration above 10^{-8} M.

165-484. (Cancelled)

485. (Withdrawn and Previously Presented) The method of claim 13, further comprising administering to the subject an anti-microbial agent.

486. (Withdrawn and Previously Presented) The method of claim 485, wherein the anti-microbial agent is an anti-bacterial agent.

487. (Withdrawn and Previously Presented) The method of claim 485, wherein the anti-microbial agent is an anti-viral agent.

488. (Withdrawn and Previously Presented) The method of claim 485, wherein the anti-microbial agent is an anti-fungal agent.

489. (Withdrawn and Previously Presented) The method of claim 485, wherein the anti-microbial agent is an anti-parasitic agent.

490. (Withdrawn and Previously Presented) The method of claim 485, wherein the anti-microbial agent is an anti-mycobacterial agent.

491. (Withdrawn and Previously Presented) The method of claim 164, further comprising administering to the subject a microbial antigen.

492. (Withdrawn and Previously Presented) The method of claim 491, wherein the microbial antigen is a bacterial antigen.


493. (Withdrawn and Previously Presented) The method of claim 491, wherein the microbial antigen is a viral antigen.

494. (Withdrawn and Previously Presented) The method of claim 491, wherein the microbial antigen is a fungal antigen.

495. (Withdrawn and Previously Presented) The method of claim 491, wherein the microbial antigen is a mycobacterial antigen.


496. (Withdrawn and Previously Presented) The method of claim 491, wherein the microbial antigen is a parasitic antigen.

497. (Withdrawn and Currently Amended) The method of claim 13, wherein the agent of Formula I is




an agent of Formula II .

498. (Withdrawn and Currently Amended) The method of claim 164, wherein the agent of Formula I is




an agent of Formula II .

499. (Withdrawn and Currently Amended) The method of claim 13, wherein the agent of Formula I is



an agent of Formula III .

500. (Withdrawn and Currently Amended) The method of claim 164, wherein the agent of Formula I is



~~an agent of Formula II .~~

501. (Previously Presented) The method of claim 13, wherein the agent of Formula I is Ile-boroPro.

502. (Previously Presented) The method of claim 164, wherein the agent of Formula I is Ile-boroPro.

503. (Previously Presented) The method of claim 13, wherein injection is subcutaneous injection.

504. (Previously Presented) The method of claim 164, wherein injection is subcutaneous injection.

505. (Previously Presented) The method of claim 13, wherein injection is intravenous injection, intramuscular injection, or intraperitoneal injection.

506. (Previously Presented) The method of claim 164, wherein injection is intravenous injection, intramuscular injection, or intraperitoneal injection.

507. (Withdrawn and Previously Presented) The method of claim 13, wherein the enterically coated form is a pill, a capsule or a tablet.

508. (Withdrawn and Previously Presented) The method of claim 164, wherein the enterically coated form is a pill, a capsule or a tablet.

509. (Previously Presented) The method of claim 13, wherein the effective amount is about 0.005 mg/kg to less than 1.0 mg/kg body weight per day.

510. (Previously Presented) The method of claim 164, wherein the effective amount is about 0.005 mg/kg to less than 1.0 mg/kg body weight per day.

511. (Currently Amended) The method of claim 13, wherein at least 96% of the agents comprise an A₁ bonded to the R with a C bond that is in the L-configuration ~~of Formula I is at least 96% pure L-isomer.~~

512. (Currently Amended) The method of claim 164, wherein at least 96% of the agents comprise an A₁ bonded to the R with a C bond that is in the L-configuration ~~of Formula I is at least 96% pure L-isomer.~~

513.-514. (Cancelled)

515. (Previously Presented) The method of claim 13, wherein the agent of Formula I is administered in an amount that increases lymphoid tissue levels of IL-1, G-CSF or IL-8.

516. (Previously Presented) The method of claim 164, wherein the agent of Formula I is administered in an amount that increases lymphoid tissue levels of IL-1, G-CSF or IL-8.

517. (Previously Presented) The method of claim 13, wherein the agent of Formula I is administered in an amount that does not increase serum IL-1 levels.

518. (Previously Presented) The method of claim 164, wherein the agent of Formula I is administered in an amount that does not increase serum IL-1 levels.

519. (Previously Presented) The method of claim 13, wherein the agent of Formula I is administered at a concentration of greater than 10⁻⁸M.

520. (Previously Presented) The method of claim 164, wherein the agent of Formula I is administered at a concentration of greater than 10⁻⁸M.